These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 27900610

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
    Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Müller K, Roessig L, Gheorghiade M, SOCRATES Investigators and Coordinators.
    Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511
    [Abstract] [Full Text] [Related]

  • 27. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P, Becker-Pelster EM, Stasch JP.
    Nitric Oxide; 2018 Jul 01; 77():88-95. PubMed ID: 29738821
    [Abstract] [Full Text] [Related]

  • 28. Vericiguat: First Approval.
    Markham A, Duggan S.
    Drugs; 2021 Apr 01; 81(6):721-726. PubMed ID: 33770393
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
    Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, Freitas C, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F.
    Eur J Heart Fail; 2022 Nov 01; 24(11):2029-2036. PubMed ID: 36250238
    [Abstract] [Full Text] [Related]

  • 31. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.
    Benza R, Mathai S, Nathan SD.
    Respir Med; 2017 Jan 01; 122 Suppl 1():S28-S34. PubMed ID: 27890470
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM, Price GM, Liu G, Sarno R, Buys ES, Currie MG, Masferrer JL.
    Am J Physiol Renal Physiol; 2020 Jan 01; 318(1):F148-F159. PubMed ID: 31608671
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.
    Liang WL, Liang B.
    Curr Cardiol Rep; 2023 Jun 01; 25(6):607-613. PubMed ID: 37079245
    [Abstract] [Full Text] [Related]

  • 36. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
    Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF, Lombardi CM, Passino C, Cerbai E, Metra M, Senni M.
    J Am Coll Cardiol; 2020 Oct 13; 76(15):1795-1807. PubMed ID: 33032741
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
    Stasch JP, Schlossmann J, Hocher B.
    Curr Opin Pharmacol; 2015 Apr 13; 21():95-104. PubMed ID: 25645316
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.